2011 Pharmaceuticals Research Review
- The global market for marine-derived drugs by type was around $4.8 billion in 2011, which is expected to be around $5.3 billion in 2012. This global market is forecasted to reach $8.6 billion by 2016 at a compound annual growth rate (CAGR) of 12.5% for the five year period of 2011 to 2016.
- The overall emerging markets for therapeutic drugs totaled $131.4 billion in 2009. These regions include Latin America, China, Eastern Europe, the Middle East, South Korea, India, Russia, and South Africa. These regions are estimated at $145.8 billion in 2010 and expected to continue aggressive growth through 2015, reaching a figure of $214.2 billion, yielding a compound annual growth rate (CAGR) of 8% from 2010 to 2015.
- The global market for blood-brain barrier (BBB) technology for therapeutics amounted to $12.3 million in 2010 and will reach $387 million by 2015, a compound annual growth rate (CAGR) of 99.3%.
The pharmaceutical industry continues to twist and turn toward the sunlight, and away from the darkness of the patent cliff. As growth rates slow, alarm is never far from the lips. Purchasing power within middle-income families in BRIC countries (Brazil, Russia, India, and China) is often described as being just what the doctor ordered, but in truth “blockbuster” means something far smaller here, while affordability and IP issues become more pressing.
Some companies pursue new classes of therapy by exploring ways to enter the blood brain barrier with specialized formulations or procedures, which may reawaken the concept of lifestyle drugs. Others keep the light burning by looking for ways to deliver RNAi and stem cell therapies. Still others dredge the vast oceans for novel chemical entities. Ultimately, innovation is the only sure cure for stalled sales.
BCC Research has provided comprehensive coverage of pharmaceutical markets for many years, and we are now increasing our coverage of global pharmaceutical markets. This review of pharmaceutical market research conducted in 2011 is meant to provide a sampling of the type of quantitative market information, analysis and guidance that has been aiding business decision-making since BCC was founded in 1971.
This review includes highlights from the following reports on pharmaceutical markets published BCC Research:
- Global Markets for Marine-Derived Pharmaceuticals
- Emerging Regional Markets for Therapeutic Drugs
- Blood-Brain Barrier Technologies and Global Markets
- Drugs for Treating Mental Disorders: Technologies and Global Markets
- Generic Drugs: The Global Market
- Vaccine Technologies and Global Markets
- The Clinical Trials Business
We hope you find this Research Review valuable, and we look forward to serving our customers’ pharmaceutical market research needs.
The global ophthalmic market grew to $15.5 billion in 2009, showing resistance to the global recession. The sector will continue to grow through 2014 to $20.6 billion, a compound annual growth rate (CAGR) of 5.9%.
Total sales of drug-device combination products worldwide were valued at $12 billion in 2008. The overall market is increasing at a compound annual growth rate (CAGR) of 14.5% per year and thus sales are projected to reach $27 billion by 2014. Overall, sales in the U.S. represent about a third of total industry revenues.
The global cardiovascular market was valued at $140.7 billion in 2009, and is expected to continue to grow in 2010 to $144.5 billion by a compound annual growth rate (CAGR) of 2.7%. The sector will experience a sizable reduction in the early portion of the forecast period, and then slowly rise to a net small reduction by 2015 on a CAGR basis of -0.7%, to a figure of $139.8 billion.